Cargando…
Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study
In a comparative oncology study with progression-free or overall survival as the endpoint, the primary or key secondary analysis is routinely stratified by patients’ baseline characteristics when evaluating the treatment difference. The validity of a conventional strategy such as a stratified HR ana...
Autores principales: | Sun, Ryan, McCaw, Zachary, Tian, Lu, Uno, Hajime, Hong, Fangxin, Kim, Dae Hyun, Wei, Lee-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606770/ https://www.ncbi.nlm.nih.gov/pubmed/34799398 http://dx.doi.org/10.1136/jitc-2021-003323 |
Ejemplares similares
-
Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
por: McCaw, Zachary R, et al.
Publicado: (2022) -
Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
por: Uno, Hajime, et al.
Publicado: (2019) -
Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies
por: Wang, Xiaofei, et al.
Publicado: (2023) -
Assuring the quality of programmatic assessment: Moving beyond psychometrics
por: Uijtdehaage, Sebastian, et al.
Publicado: (2018) -
Commentary: Moving beyond phenotypic diagnosis
por: Stansfield, William E.
Publicado: (2020)